J. Grandis

J. Grandis, V. Yu, M. Wagener, 1992, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study

J. Grandis, Marie Murphy, D. Dohan, 2021, Academic medicine : journal of the Association of American Medical Colleges.

of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in and

J. Grandis, J. Califano, M. Gilardi, 2021 .

Clinical trials optimizing investigator and self‐collection of buccal cells for RNA yield

J. Grandis, Hua Li, J. Bauman, 2021, Laryngoscope investigative otolaryngology.

cells for RNA yield.

J. Grandis, J. Bauman, D. Normolle, 2021 .

Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck.

J. Siegfried, J. Grandis, S. El-Sayed, 2005, Oral oncology.

Kinin B2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas

J. Siegfried, R. Seethala, J. Grandis, 2008, Molecular Cancer Research.

Kinin B 2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas

J. Siegfried, R. Seethala, J. Grandis, 2008 .

Constitutive activation of Stat5b contributes to carcinogenesis in vivo.

J. Grandis, S. Xi, T. Smithgall, 2003, Cancer research.

Levels of TGF- (cid:97) and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

R. Day, J. Grandis, D. Tweardy, 1998 .

Systematic prediction of human membrane receptor interactions

Yanjun Qi, Ziv Bar-Joseph, Judith Klein-Seetharaman, 2009, Proteomics.

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.

J. Siegfried, J. Grandis, D. Chan, 2006, Cancer research.

WHO classification of head and neck tumours

J. Grandis, J. Chan, P. Slootweg, 2017 .

Emerging tyrosine kinase inhibitors for head and neck cancer

J. Grandis, Daniel E. Johnson, Zhen Long, 2022, Expert opinion on emerging drugs.

Molecular mediators of metastasis in head and neck squamous cell carcinoma.

J. Grandis, Gina M. Howell, Gina M S Howell, 2005, Head & neck.

Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.

J. Grandis, Mengfeng Li, W. Gooding, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The role of epidermal growth factor receptor in head and neck squamous cell carcinoma

J. Grandis, R. Pomerantz, 2003, Current oncology reports.

Epidermal Growth Factor Receptor-stimulated Activation of Phospholipase C-1 Promotes Invasion of Head and Neck Squamous Cell Carcinoma 1

J. Grandis, A. Wells, J. Kassis, 2003 .

Lack of toxicity of EGFR antisense gene therapy.

R. Dhir, J. Grandis, Leaf Huang, 2002, Journal of experimental therapeutics & oncology.

Differential function of STAT5 isoforms in head and neck cancer growth control

J. Grandis, S. Xi, T. Smithgall, 2002, Oncogene.

Expression of Androgen Receptor, Epidermal Growth Factor Receptor, and Transforming Growth Factor a in Salivary Duct Carcinoma

J. Grandis, E. Barnes, C. Fan, 2001 .

Gene Therapy for the Treatment of Oral Squamous Cell Carcinoma

J. Grandis, S. Xi, J. Grandis, 2003, Journal of dental research.

COX-2, cell proliferation and PMA in head-and-neck cancer cells

F. B. Davis, J. Grandis, Hung-Yun Lin, 2009 .

Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility.

J. Grandis, T. Billiar, J. Kalff, 2004, Gastroenterology.

Altered inflammatory gene expression underlies increased susceptibility to murine postoperative ileus with advancing age.

J. Grandis, B. Davis, K. Albers, 2007, American journal of physiology. Gastrointestinal and liver physiology.

Tyrphostin AG 126 inhibits development of postoperative ileus induced by surgical manipulation of murine colon.

J. Grandis, A. Bauer, A. Türler, 2004, American journal of physiology. Gastrointestinal and liver physiology.

Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.

J. Grandis, R. Ferrell, J. Hunt, 2007, Journal of the National Cancer Institute.

Requirement of Stat 3 but not Stat 1 Activation for Epidermal Growth Factor Receptor – mediated Cell Growth In Vitro

J. Grandis, D. Tweardy, A. Chakraborty, 1998 .

Head and neck cancer: recent advances and new standards of care.

J. Grandis, D. Pfister, A. Trotti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Head and Neck Cancer: Recent Advances and New

J. Grandis, D. Pfister, A. Trotti, 2006 .

Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience

D. Heron, R. Carrau, J. Grandis, 2009, The Laryngoscope.

Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

J. Grandis, A. Sepulveda, M. Mapara, 2011, Cellular immunology.

Biopsy of Minor Salivary Glands of the Lip

J. Grandis, R. Fraioli, 2008 .

Prognostic factors in patients with high‐risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy

D. Heron, J. Grandis, R. Ferris, 2011, Head & neck.

Understanding the presence and function of erythropoietin receptors on cancer cells.

J. Grandis, S. Lai, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus.

J. Grandis, M. Eskandari, J. Kalff, 2002, Gastroenterology.

To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwarski, J. Grandis, D. Xiao, 2014, Clinical Cancer Research.

Head and neck cancer in 2016: A watershed year for improvements in treatment?

J. Grandis, A. Algazi, 2017, Nature Reviews Clinical Oncology.

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

J. Grandis, R. Ferris, S. Ferrone, 2009, Cancer Immunology, Immunotherapy.

Combined Targeting of EGFR , STAT 3 , and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck

Shaomeng Wang, R. Seethala, J. Grandis, 2008 .

The role of CD44 in HNSCC

J. Grandis, A. Nelson, 2007, Cancer biology & therapy.

Long‐Term Results of a Phase III Randomized Trial of Postoperative Radiotherapy With or Without Carboplatin in Patients With High‐Risk Head and Neck Cancer

D. Heron, M. Karamouzis, J. Grandis, 2008, The Laryngoscope.

Networking practices and gender inequities in academic medicine: Women's and men's perspectives

J. Grandis, Marie Murphy, D. Dohan, 2022, EClinicalMedicine.

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer

J. Grandis, Daniel E. Johnson, Nathan K. VanLandingham, 2022, Advances in Biological Regulation.

Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl‐2 expression and increased susceptibility to cisplatin‐induced apoptosis

J. Grandis, D. Sidransky, S. Xi, 2004, Head & neck.

Treatment of Infections of the Ears, Nose, and Throat and Nasal Carriage

J. Grandis, V. Yu, 2003 .

PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma

Simion I. Chiosea, J. Grandis, M. Nikiforova, 2013, BMC Cancer.

Endoscopic Sphenopalatine Artery Ligation is an Effective Method of Treatment for Posterior Epistaxis

C. Snyderman, R. Carrau, J. Grandis, 1999, American journal of rhinology.

Necrotizing (malignant) external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up.

J. Grandis, V. Yu, H. Curtin, 1995, Radiology.

MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling

Chun Kit Yeung, Yuchen Liu, G. Mills, 2020, Life Science Alliance.

Simultaneous presentation of malignant external otitis and temporal bone cancer.

J. Grandis, V. Yu, B. Hirsch, 1993, Archives of otolaryngology--head & neck surgery.

Efficacy of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate and clindamycin in contaminated head and neck surgery: effect of antibiotic spectra and duration of therapy.

J. Johnson, J. Grandis, V. Yu, 1994, The Journal of infectious diseases.

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Jennifer R. Grandis, J. Grandis, Daniel E. Johnson, 2018, Nature Reviews Clinical Oncology.

Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors.

Vsevolod A. Peshkov, P. Wipf, J. Grandis, 2016, Bioorganic & medicinal chemistry letters.

Epidermal growth factor receptor biology in head and neck cancer.

J. Grandis, Jennifer R Grandis, Shailaja Kalyankrishna, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

J. Grandis, S. Thomas, S. Thomas, 2004, Cancer treatment reviews.

MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index.

Scott M Langevin, R. Stone, J. Grandis, 2010, Carcinogenesis.

Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer

C. Snyderman, J. Grandis, F. D'amico, 1992, Cancer.

MicroRNA‐137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck

R. Stone, R. Seethala, J. Grandis, 2011, Cancer.

Research education and training in otolaryngology: Meeting summary and research opportunities

J. Battey, W. Kapoor, R. Califf, 2006, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection

J. Grandis, R. Ferris, T. Whiteside, 2007, Head & neck.

Head and neck squamous cell carcinoma

J. Grandis, C. Leemans, J. Bauman, 2020, Nature Reviews Disease Primers.

The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

J. Grandis, S. Wells, L. Romick-Rosendale, 2013, Mutation research.

JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth12

Simion I. Chiosea, J. Grandis, S. Chiosea, 2015, Neoplasia.

STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.

J. Grandis, S. Xi, W. Gooding, 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Cancer Cell Lines RXR-selective Retinoid ( LGD 1069 , Targretin ) in Head and Neck Growth Factor Receptor Autocrine Signaling by an / Epidermal α Abrogation of Transforming Growth Factor-Updated

J. Grandis, M. Lango, Q. Zeng, 2001 .

In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy

J. Grandis, S. Xi, W. Gooding, 2005, Oncogene.

ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated Pathway

J. Grandis, Neil S. Patel, Rongxiu Li, 2009, Molecular Pharmacology.

Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.

Daniel B. Neill, D. Neill, R. Seethala, 2009, Carcinogenesis.

STAT3 signaling: anticancer strategies and challenges.

J. Grandis, P. Johnston, 2011, Molecular interventions.

Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

J. Grandis, R. Ferris, A. Wells, 2005, Oncogene.

Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors

Daniel B. Neill, D. Neill, J. Grandis, 2010, Clinical Cancer Research.

Head and neck squamous cell carcinoma

C. R. Leemans, J. Grandis, C. Leemans, 2020, Nature Reviews Disease Primers.

STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines

J. Grandis, A. Wells, W. Zhou, 2006, British Journal of Cancer.

Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer

J. Grandis, Hua Li, Zhiyong Wang, 2020, Molecular Cancer Therapeutics.

Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma

P. Hammerman, A. Egloff, Lin Wang, 2015, PloS one.

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Jennifer L Hunt, D. Bigner, J. Grandis, 2006, Clinical Cancer Research.

Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction

J. Grandis, Daniel E. Johnson, Z. Cui, 2021, Cell Death & Disease.

The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

J. Grandis, J. Bauman, J. Geiger, 2016, Oral oncology.

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer

J. Grandis, T. Chan, Hua Li, 2015, PloS one.

Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer

Kelsey P. Pendleton, G. Mills, L. Garraway, 2014, Proceedings of the National Academy of Sciences.

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Simion I. Chiosea, Kelsey P. Pendleton, G. Mills, 2013, Cancer discovery.

Prognostic Biomarkers in Head and Neck Cancer

J. Grandis, 2006, Clinical Cancer Research.

Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma

J. Grandis, B. Warner, 2016 .

3 – Molecular Biology

J. Grandis, D. Clayburgh, 2018 .

Molecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer Therapy

A. Egloff, J. Grandis, 2012, Clinical Cancer Research.

NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.

J. Grandis, Daniel E. Johnson, A. Yousef, 2020, Advances in biological regulation.

PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs

J. Grandis, J. S. Gutkind, Daniel E. Johnson, 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.

Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection

Levi A Garraway, Vivian Wai Yan Lui, Hua Li, 2014, Molecular Cancer Research.

Phospholipase C-γ1 in tumor progression

J. Grandis, A. Wells, 2003, Clinical & Experimental Metastasis.

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

J. Grandis, Hua Li, C. Arteaga, 2016, Cancer research.

PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells

Jian Yu, J. Grandis, Z. Chen, 2009, Oncogene.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

Title Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

Simion I. Chiosea, R. Herbst, Lin Wang, 2015 .

New Therapies in Head and Neck Cancer.

J. Grandis, Daniel E. Johnson, Rodell T Santuray, 2018, Trends in cancer.

Targeting the JAK/STAT pathway in solid tumors

J. Grandis, Daniel E. Johnson, Z. Qureshy, 2020, Journal of cancer metastasis and treatment.

Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

J. Grandis, Daniel E. Johnson, N. Jin, 2020, Biochimica et biophysica acta. Molecular cell research.

EGFR-targeted therapies in the post-genomic era

J. Grandis, M. Xu, Daniel E. Johnson, 2017, Cancer and Metastasis Reviews.

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies

Lin Wang, J. Grandis, Hua Li, 2015, Clinical Cancer Research.

HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

J. Grandis, Netanya I Pollock, 2014, Clinical Cancer Research.

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

G. Mills, J. Siegfried, A. Egloff, 2012, Clinical Cancer Research.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

R. McLendon, Hai Yan, D. Bigner, 2014, The Journal of clinical investigation.

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

M. Karamouzis, J. Grandis, A. Argiris, 2007, JAMA.

ErbB receptors in the biology and pathology of the aerodigestive tract.

J. Grandis, Sarah Morgan, 2009, Experimental cell research.

Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

G. Mills, Yiling Lu, J. Grandis, 2014, Oncogene.

Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR

W. Rom, J. Siegfried, J. Grandis, 2010, Clinical Cancer Research.

STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma

J. Grandis, Seungwon Kim, J. Myers, 2014, PloS one.

Critical analysis of the potential for targeting STAT3 in human malignancy

J. Grandis, N. Peyser, 2013, OncoTargets and therapy.

Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy

J. Grandis, Daniel E. Johnson, Rachel A O'Keefe, 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.

Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy.

D. Heron, J. Johnson, J. Grandis, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.

J. Grandis, Hua Li, Yan Zeng, 2018, Cancer research.

The Molecular Pathogenesis of Head and Neck Cancer

J. Grandis, J. Klein, 2010, Cancer biology & therapy.

STAT signaling in head and neck cancer

J. Grandis, Jennifer Rubin Grandis, John I Song, 2000, Oncogene.

EGFR-targeted therapies in the post-genomic era

J. Grandis, M. Xu, Daniel E. Johnson, 2017, Cancer and Metastasis Reviews.

Investigational multitargeted kinase inhibitors in development for head and neck neoplasms

J. Grandis, Daniel E. Johnson, A. Šola, 2019, Expert opinion on investigational drugs.

STAT3 as a therapeutic target in head and neck cancer

J. Grandis, V. W. Lui, R. Leeman, 2006, Expert opinion on biological therapy.

ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin.

J. Grandis, Hua Li, C. Bakkenist, 2019, Oral oncology.

PROSPECTIVE Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas

D. Hayes, P. Hammerman, J. Grandis, 2015 .

Discovering dominant tumor immune archetypes in a pan-cancer census

E. Nakakura, A. Olshen, S. Asthana, 2021, Cell.

Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines

P. Wipf, J. Grandis, D. Huryn, 2017, Journal of chemical biology.

Association of the EGFR intron 1 CA repeat length with lung cancer risk

J. Siegfried, M. Romkes, J. Weissfeld, 2007, Molecular carcinogenesis.

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

J. Siegfried, M. Romkes, J. Grandis, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multiple Cytokine and Growth Factor Serum Biomarkers Predict Therapeutic Response and Survival in Advanced-Stage Head and Neck Cancer Patients

J. Siegfried, J. Grandis, W. Bigbee, 2007, Clinical Cancer Research.

Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

J. Grandis, A. Cassell, 2010, Expert opinion on investigational drugs.

STAT‐mediated EGFR signaling in cancer

J. Grandis, K. Quesnelle, Amanda L. Boehm, 2007, Journal of cellular biochemistry.

Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

J. Siegfried, J. Grandis, L. Stabile, 2005, Cancer research.

Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial‐based therapeutics

J. Grandis, S. Yom, A. Radaic, 2021, Periodontology 2000.

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

J. Grandis, M. Hung, Yueh-Fu Fang, 2015, The Journal of clinical investigation.

Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.

J. Grandis, P. Harari, D. Wheeler, 2009, Seminars in radiation oncology.

Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer

A. Olshan, W. Ahrens, S. Franceschi, 2016, Nature Genetics.

Therapeutic i nsights from Genomic s tudies of Head and Neck s quamous Cell Carcinomas

D. Hayes, P. Hammerman, J. Grandis, 2015 .

Nucleic acid-based approaches to STAT inhibition

J. Grandis, Malabika Sen, 2012, JAK-STAT.

Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth

J. Grandis, P. Robbins, S. Xi, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer

Lin Wang, J. Grandis, Daniel E. Johnson, 2015, Oncogene.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Simion I. Chiosea, Kelsey P. Pendleton, A. McKenna, 2015, JAMA oncology.

Targeting Angiogenesis from Premalignancy to Metastases

J. Grandis, A. Argiris, 2009, Cancer Prevention Research.

Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.

G. Mills, J. Siegfried, J. Grandis, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells

J. Siegfried, J. Grandis, S. Xi, 2004, Cancer Research.

Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.

J. Grandis, S. Shangary, Rongxiu Li, 2007, Neoplasia.

HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment

J. Grandis, N. Bhola, S. Hartmann, 2016, Clinical Cancer Research.

Determinants of head and neck cancer survival by race

Scott M Langevin, J. Grandis, E. Taioli, 2011, Head & neck.

Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.

Kelsey P. Pendleton, J. Grandis, 2013, Clinical medicine insights. Therapeutics.

Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer

J. Grandis, Anirban Sahu, S. Thomas, 2012, Molecular Cancer Therapeutics.

Anti-tumor mechanisms of targeting the PDK1 pathway in head and neck cancer

J. Grandis, Anirban Sahu, S. Thomas, 2012 .

Nucleic Acid Targeting: Towards Personalized Therapy for Head and Neck Cancer

J. Grandis, S. Thomas, Sean M. Parsel, 2015, Oncogene.

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

G. Mills, Z. Ju, Yiling Lu, 2017, Science Translational Medicine.

Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

G. Sica, F. Khuri, J. Grandis, 2013, Clinical Cancer Research.

Epidermal growth factor receptor – targeted molecular therapeutics for head and neck squamous cell carcinoma

A. Egloff, J. Grandis, 2006, Expert opinion on therapeutic targets.

Frequent Mutation of the PI 3 K Pathway in Head and Neck Cancer Defi nes Predictive Biomarkers

Kelsey P. Pendleton, G. Mills, L. Garraway, 2013 .

Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.

J. Grandis, N. Bhola, 2008, Frontiers in bioscience : a journal and virtual library.

Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium.

J. Grandis, D. Tweardy, D. Johnson, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Growth and differentiation of rat hepatocytes: changes in transcription factors HNF-3, HNF-4, STAT-3, and STAT-5.

J. Grandis, G. Michalopoulos, W. Bowen, 1998, Biochemical and biophysical research communications.

Molecular changes in the multistage pathogenesis of head and neck cancer.

Simion I. Chiosea, Brian J. Park, J. Grandis, 2010, Cancer biomarkers : section A of Disease markers.

Receptor-type protein tyrosine phosphatases in cancer

J. Grandis, Yu Du, 2015, Chinese journal of cancer.

Title Loss-of-Function PTPRD Mutations Lead to Increased STAT 3 Activation and Sensitivity to STAT 3 Inhibition in Head and Neck Cancer

J. Grandis, T. Chan, Hua Li, 2015 .

Title Identification of Mutations in the PYRIN-Containing NLR Genes ( NLRP ) in Head and Neck Squamous Cell Carcinoma

A. Egloff, J. Grandis, Y. Lei, 2014 .

CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus–Associated Head and Neck Cancers

J. Grandis, Daniel E. Johnson, Hyunseok Kang, 2020, Molecular Cancer Research.

The impact of health insurance status on the survival of patients with head and neck cancer

Scott M Langevin, J. Grandis, A. Argiris, 2010, Cancer.

Stat3 activation in prostatic carcinomas

R. Dhir, J. Grandis, A. Gao, 2002, The Prostate.

Transcription Factors and Cancer

J. Grandis, Daniel E. Johnson, Jamie V Shiah, 2023, Cancer journal.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer

J. Grandis, S. Wheeler, K. Quesnelle, 2012, Cancer biology & therapy.

MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer

J. Grandis, R. Ferris, Jingjing Xu, 2015, BMC Cancer.

The efficacy of topical antibiotic prophylaxis for contaminated head and neck surgery

J. Grandis, V. Yu, J. Rihs, 1994, The Laryngoscope.

Emerging drugs for head and neck cancer

J. Grandis, Y. Wen, 2015, Expert opinion on emerging drugs.

Emerging drugs to treat squamous cell carcinomas of the head and neck

J. Grandis, C. Fung, 2010, Expert opinion on emerging drugs.

Aberrant kinase signaling: lessons from head and neck cancer.

J. Grandis, Elizabeth G Nelson, 2007, Future oncology.

Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck*

J. Grandis, S. Xi, T. Smithgall, 2003, Journal of Biological Chemistry.

Tumor Growth and Metastasis in SCCHN To " Grow " or " Go " : TMEM 16 A Expression as a Switch between

Daniel J. Shiwarski, J. Grandis, U. Duvvuri, 2014 .

Biology of Human Tumors To " Grow " or " Go " : TMEM 16 A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwarski, J. Grandis, D. Xiao, 2014 .

TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression.

Xin Huang, Dong Xiao, Umamaheswar Duvvuri, 2012, Cancer research.

Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting

J. Grandis, S. Xi, Raymond L. Chai, 2008, Clinical Cancer Research.

Role of Subglottic Injury, Gastric Juice, and Peptide Growth Factors in a Porcine Model

J. Grandis, P. Dickman, Robert F. Yellon, 1997, International Anesthesiology Clinics.

Epidermal Growth Factor Receptor-Targeted Therapies

J. Grandis, Seungwon Kim, S. Ahn, 2011 .

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation

D. Bigner, J. Grandis, S. Lai, 2009, Oncogene.

Activation of STATs 3 and 5 Through the EGFR Signaling Axis

J. Grandis, Priya Koppikar, 2008 .

Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer

Kelsey P. Pendleton, J. Grandis, Daniel E. Johnson, 2016, PloS one.

Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

R. Seethala, Lin Wang, J. Grandis, 2011, Oral oncology.

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance

J. Grandis, K. Quesnelle, Kelly M. Quesnelle, 2011, Clinical Cancer Research.

Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

J. Grandis, A. Hemminki, E. Cohen, 2010, Clinical Cancer Research.

Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck

J. Grandis, S. Strychor, W. Zamboni, 2008, Molecular Pharmacology.

Cancer Therapy : Preclinical cSrc Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

J. Siegfried, J. Grandis, M. Thomas, 2013 .

Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery

Adrian V. Lee, Timothy R. Lezon, Jennifer R. Grandis, 2014, PloS one.

STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer

J. Siegfried, J. Grandis, Daniel E. Johnson, 2018, Molecular Cancer Therapeutics.

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations

Simion I. Chiosea, P. Hammerman, Lin Wang, 2017, Nature Communications.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

A. Egloff, Lin Wang, J. Grandis, 2017, Oral oncology.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Simion I. Chiosea, G. Mills, A. Jimeno, 2017, JCI insight.

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients

J. Grandis, Seungwon Kim, J. Bauman, 2019, Clinical Cancer Research.

Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives

D. Heron, J. Grandis, Seungwon Kim, 2018, Cancer.

Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells

J. Siegfried, J. Grandis, Hai-Yan Xu, 2011, Clinical Cancer Research.

STAT 3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma

J. Grandis, Seungwon Kim, J. Myers, 2013 .

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

M. Romkes, R. Seethala, Lin Wang, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

M. Romkes, R. Seethala, Lin Wang, 2011 .

A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity

T. Ideker, N. Krogan, Jisoo Park, 2021, Science.

Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides

J. Grandis, Daniel E. Johnson, Jamie V Shiah, 2020, Molecular Cancer Therapeutics.

Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

J. Grandis, R. Ferris, A. Argiris, 2012, Oral oncology.

Dental infections

J. Grandis, Jonas T. Johnson, B. Hathaway, 2021, Schlossberg's Clinical Infectious Disease.

Mutational Profile of HPV-Positive HNSCC

J. Grandis, Hua Li, 2015 .

Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.

J. Grandis, Daniel E. Johnson, Y. Zang, 2014, Oral oncology.

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer

J. Grandis, A. Porgador, B. Rotblat, 2021, Cancers.

Prognostic biomarkers in patients with human immunodeficiency virus‐positive disease with head and neck squamous cell carcinoma

Amy Y. Chen, G. Sica, J. Lee, 2017, Head & neck.

Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) Polymorphism on Outcome of Advanced-Stage Squamous Cell Carcinoma of the Head and Neck Are Treatment Dependent

S. Zhong, L. Weissfeld, M. Romkes, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

J. Grandis, D. Tweardy, E. Barnes, 1996, Cancer.

Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.

D. Heron, R. Seethala, Lin Wang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.

G. Mills, J. Mountz, A. Egloff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Issues in Moving Gene Therapy Approaches to Early Clinical Trials

J. Grandis, S. Gerson, S. Thomas, 2014 .

Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.

J. Grandis, Mengfeng Li, Q. Zeng, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Subglottic Injury, Gastric Juice, Corticosteroids, and Peptide Growth Factors in a Porcine Model

J. Grandis, P. Dickman, W. Szeremeta, 1998, The Laryngoscope.

Resveratrol causes COX‐2‐ and p53‐dependent apoptosis in head and neck squamous cell cancer cells

F. B. Davis, J. Grandis, P. Davis, 2008, Journal of cellular biochemistry.

Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.

J. Grandis, P. Dent, A. Yacoub, 2005, Biochemical pharmacology.

Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth

Jonathan A. Kopechek, A. Carson, J. Grandis, 2015, Theranostics.

Title Ultrasound targeted microbubble destruction-mediated delivery of a transcription factor decoy inhibits STAT 3 signaling and tumor growth Permalink

Linda, Jonathan A. Kopechek, A. Carson, 2015 .

Leveraging Genomics for Head and Neck Cancer Treatment

J. Grandis, Daniel E. Johnson, J. Kemmer, 2018, Journal of dental research.

EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.

K. Hörmann, J. Grandis, Mengfeng Li, 2002, International journal of oncology.

Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer

J. Grandis, Dong-Myung Shin, M. Khalil, 2003, Expert review of anticancer therapy.

APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma

K. Anderson, J. Townsend, J. Grandis, 2019, Oncogene.

Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches

J. Grandis, Daniel E. Johnson, J. Kass, 2014 .

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells

J. Grandis, Rongxiu Li, Daniel E. Johnson, 2008, Molecular Cancer Therapeutics.

Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer

J. Grandis, D. Shin, M. Lango, 2001, Current opinion in oncology.

Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma

J. Weissfeld, Lin Wang, J. Grandis, 2013, Head and Neck Pathology.

Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth

J. Grandis, Huafei Zou, A. J. Mixson, 2008, Molecular Cancer Therapeutics.

Cancer Therapy : Clinical ChemopreventionofHeadandNeckCancer bySimultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways : Preclinical and Clinical Studies

Amy Y. Chen, G. Sica, F. Khuri, 2013 .

Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study

York E Miller, Yongli Shuai, Y. Miller, 2012, Respiratory Research.

c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

J. Siegfried, J. Grandis, S. Thomas, 2012, Clinical Cancer Research.

Advances in molecular diagnostics and therapeutics in head and neck cancer

J. Grandis, Raymond L. Chai, 2006, Current treatment options in oncology.

Integration of molecular targeted therapy with radiation in head and neck cancer.

J. Grandis, Yu Du, N. Peyser, 2014, Pharmacology & therapeutics.

Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer

J. Grandis, V. W. Lui, 2012, Head and Neck Pathology.

First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Simion I. Chiosea, Joanne I. Yeh, D. Ly, 2012, Cancer discovery.

Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Hanno Steen, Jayoung Kim, Wei Yang, 2010, Journal of proteome research.

An update: emerging drugs to treat squamous cell carcinomas of the head and neck

J. Grandis, Daniel E. Johnson, Yoon Se Lee, 2018, Expert opinion on emerging drugs.

Treatment of head and neck cancer in the elderly

J. Grandis, S. Hartmann, 2016, Expert opinion on pharmacotherapy.

Targeting epidermal growth factor receptor in head and neck cancer

J. Grandis, Allison Carter Ford, A. Ford, 2003 .

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Grandis, P. Harari, A. Argiris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The gender gap in a surgical subspecialty: analysis of career and lifestyle factors.

S. Mackinnon, J. Grandis, M. Wagener, 2004, Archives of otolaryngology--head & neck surgery.

Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck

J. Grandis, Z. Chen, D. Shin, 2004, Clinical Cancer Research.

Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.

J. Mountz, D. Heron, M. Karamouzis, 2009, International journal of radiation oncology, biology, physics.

Elevated gastrin‐releasing peptide receptor mRNA expression in buccal mucosa: Association with head and neck squamous cell carcinoma

J. Siegfried, A. Egloff, J. Grandis, 2013, Head & neck.

Caspase‐8 mutations in head and neck cancer confer resistance to death receptor‐mediated apoptosis and enhance migration, invasion, and tumor growth

A. Egloff, J. Grandis, Daniel E. Johnson, 2014, Molecular oncology.

New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints

V. Wang, J. Grandis, A. Ko, 2016, Clinical Cancer Research.

The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma

J. Grandis, Zhi‐hua Liu, X. Guan, 2017, Clinical Cancer Research.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

J. Grandis, A. Argiris, J. Bauman, 2016, Head & neck.

Oncogenomics/Proteomics of Head and Neck Cancers

J. Grandis, H. Moskowitz, 2011 .

Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma.

D. Weeks, Jian-Min Yuan, A. Egloff, 2015, Cancer letters.

HER 2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

J. Grandis, Netanya I Pollock, 2015 .

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Simion I. Chiosea, J. Siegfried, Lin Wang, 2014, Clinical Cancer Research.

The current state of head and neck cancer gene therapy.

J. Grandis, S. Thomas, S. Thomas, 2009, Human gene therapy.

Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy

J. Grandis, Q. Zeng, S. Thomas, 2003, Cancer Gene Therapy.

Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death

J. Grandis, Daniel E. Johnson, Rebecca J. Leeman-Neill, 2009, Molecular Cancer Therapeutics.

Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero‐digestive tract

J. Siegfried, M. Romkes, J. Grandis, 2005, Molecular carcinogenesis.

Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk.

Scott M Langevin, J. Grandis, E. Taioli, 2011, Cancer letters.

STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma

Lin Wang, J. Grandis, Hua Li, 2016, Cancer Prevention Research.

STAT 3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma

Lin Wang, J. Grandis, Hua Li, 2016 .

Childhood passive smoke exposure is associated with adult head and neck cancer.

Brenda Diergaarde, M. Romkes, J. Weissfeld, 2013, Cancer epidemiology.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer

Simion I. Chiosea, G. Mills, S. Vandenberg, 2019, The Journal of experimental medicine.

Identification of Mutations in the PYRIN-Containing NLR Genes (NLRP) in Head and Neck Squamous Cell Carcinoma

A. Egloff, J. Grandis, Y. Lei, 2014, PloS one.

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance

J. Grandis, Daniel E. Johnson, N. Bhola, 2020, PloS one.

Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma

D. Hayes, M. Prystowsky, J. Grandis, 2017, Cancer medicine.

Chapter 2 STAT Proteins in Cancer

J. Grandis, Rachel A O'Keefe, 2019 .

STAT3 as a Major Contributor to Chemoresistance

J. Grandis, Daniel E. Johnson, David S. Lee, 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor

J. Grandis, Daniel E. Johnson, P. Ha, 2018, International journal of molecular sciences.

STAT Proteins in Cancer

J. Grandis, Rachel A O'Keefe, 2016 .

Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects

Lin Wang, J. Grandis, Hua Li, 2014, Molecular medicine.

Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis

U. Dafni, A. Egloff, J. Grandis, 2010, Clinical Cancer Research.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Sourav Bandyopadhyay, N. Krogan, J. Grandis, 2018, Cancer research.

The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy

D. Heron, Yong Yang, J. Grandis, 2011, American journal of clinical oncology.

Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients

Sourav Bandyopadhyay, J. Grandis, Hua Li, 2016, Clinical Cancer Research.

Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1

J. Grandis, Daniel E. Johnson, Erin E. Childs, 2007, Molecular Pharmacology.

High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.

J. Grandis, J. Lazo, P. Johnston, 2018, Methods in molecular biology.

STAT3 activation contributes directly to Epstein‐Barr virus–mediated invasiveness of nasopharyngeal cancer cells in vitro

J. Grandis, Q. Tao, S. Tsao, 2009, International journal of cancer.

Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting STAT3: the Role of STAT1*

J. Grandis, Daniel, V. W. Lui, 2007 .

A sensible approach to targeting STAT3-mediated transcription.

J. Grandis, Daniel E. Johnson, N. Bhola, 2016, Annals of translational medicine.

Women in otolaryngology: closing the gender gap

J. Grandis, B. Ferguson, 2006, Current opinion in otolaryngology & head and neck surgery.

Head and neck cancer: meeting summary and research opportunities.

J. Grandis, J. Pietenpol, J. Greenberger, 2004, Cancer research.

Treatment of idiopathic sudden sensorineural hearing loss.

J. Grandis, M. Wagener, B. Hirsch, 1993, The American journal of otology.

Head and Neck Cancer

J. Grandis, J. Pietenpol, J. Greenberger, 2004, Cancer Research.

Human rhomboid family‐1 gene RHBDF1 participates in GPCR‐mediated transactivation of EGFR growth signals in head and neck squamous cancer cells

J. Grandis, Huafei Zou, S. Thomas, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation

J. Grandis, D. Huryn, P. Johnston, 2016, Cancer Chemotherapy and Pharmacology.

Response to Combined Molecular Targeting: Defining the Role of P-STAT3

A. Egloff, J. Grandis, 2011, Clinical Cancer Research.

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

J. Siegfried, A. Egloff, R. Seethala, 2009, Clinical Cancer Research.

First-inHuman Trial of a STAT 3 Decoy Oligonucleotide in Head and Neck Tumors : Implications for Cancer Therapy

Simion I. Chiosea, Joanne I. Yeh, D. Ly, 2012 .

Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma.

Rajiv Dhir, Wei Lou, R. Dhir, 2002, The Journal of urology.

Immunohistochemical Analysis of Phosphotyrosine Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor Autocrine Signaling Pathways in Head and Neck Cancers and Metastatic Lymph Nodes

J. Siegfried, R. Seethala, J. Grandis, 2008, Clinical Cancer Research.

Growth Factor Receptor Signaling and Metastasis of Oral Cancer

J. Grandis, Ali Razfar, 2009 .

Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

J. Grandis, J. Fridman, Bin-Bing S. Zhou, 2007, Clinical Cancer Research.

Selective Inhibition of ADAMMetalloproteases as a Novel Approach for Modulating ErbBPathways in Cancer

J. Grandis, J. Fridman, Bin-Bing S. Zhou, 2007 .

STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors

J. Grandis, Xucai Chen, F. Villanueva, 2020, PloS one.

Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.

J. Grandis, D. Smith, D. Trump, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma

Lin Wang, J. Grandis, S. Chiosea, 2018, BMC Cancer.

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.

G. Mills, N. Krogan, J. Grandis, 2021, The Journal of clinical investigation.

Genetic mutations in head and neck cancer: utilizing existing treatments.

J. Grandis, N. Peyser, 2014, Pharmacogenomics.

Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2

J. Grandis, Jennifer Rubin Grandis, Richard A Steinman, 2003, Oncogene.

Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer

Jill M. Siegfried, Doris R. Siwak, Gordon B. Mills, 2007, Molecular Cancer Therapeutics.

Modulation of the PI3K/mTOR pathways

J. Grandis, Daniel E. Johnson, Janice M. Cho, 2020 .

Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts

A. Olshen, J. Grandis, Hua Li, 2023, PloS one.

The Role of Topical Antibiotic Prophylaxis in Patients Undergoing Contaminated Head and Neck Surgery With Flap Reconstruction

J. Grandis, J. Simons, E. Myers, 2001, The Laryngoscope.

High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

J. Grandis, J. Lazo, P. Johnston, 2014, Assay and drug development technologies.

Antibiotics in head and neck oncology

J. Grandis, Jonas T. Johnson, 1995 .

New advances in molecular approaches to head and neck squamous cell carcinoma

J. Grandis, Nivedita Sahu, 2011, Anti-cancer drugs.

Frameless Stereotactic Radiosurgery for Recurrent Head and Neck Carcinoma

D. Heron, J. Grandis, R. Ferris, 2006, Technology in cancer research & treatment.

TMEM16A/ANO1 suppression improves response to antibody‐mediated targeted therapy of EGFR and HER2/ERBB2

K. Davis, J. Grandis, U. Duvvuri, 2017, Genes, chromosomes & cancer.

NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models

J. Grandis, Hua Li, Daniel E. Johnson, 2022, Cancers.

The degree of intratumor mutational heterogeneity varies by primary tumor sub-site

Simion I. Chiosea, G. Mills, J. Grandis, 2016, Oncotarget.

Women’s Experiences of Promotion and Tenure in Academic Medicine and Potential Implications for Gender Disparities in Career Advancement

J. Grandis, Marie Murphy, D. Dohan, 2021, JAMA network open.

Author Correction: Head and neck squamous cell carcinoma

C. R. Leemans, J. Grandis, J. Bauman, 2023, Nature Reviews Disease Primers.

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma: Opportunities for Detection and Monitoring Via Analysis of Circulating Tumor DNA

J. Grandis, Daniel E. Johnson, Kelechi Nwachuku, 2021 .

Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

J. Grandis, Hua Li, C. Arteaga, 2019, Cancer Research.

PD-1+CXCR5−CD4+ Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma

J. Grandis, M. Zeng, Q. Zhong, 2021, Journal for ImmunoTherapy of Cancer.

2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway.

P. Wipf, J. Grandis, D. Huryn, 2014, Bioorganic & Medicinal Chemistry Letters.

Phospholipase C-gamma1 in tumor progression.

J. Grandis, A. Wells, 2003, Clinical & experimental metastasis.

Molecular and Cellular Pathobiology TMEM 16 A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression

A. Egloff, J. Grandis, B. Harfe, 2012 .

The non-coding landscape of head and neck squamous cell carcinoma

Andrew Hinton, Jessica Wang-Rodriguez, Jennifer R. Grandis, 2016, Oncotarget.

Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A. Egloff, J. Grandis, J. Bauman, 2016 .

Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions

Charles Laymon, James M. Mountz, Matthew J. Oborski, 2014, PloS one.

PD‐L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance

J. Grandis, Daniel E. Johnson, N. Bhola, 2021, Head & neck.

Abstract 1117: Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas.

D. Hayes, J. Grandis, A. El-Naggar, 2013 .

Human papillomavirus and head and neck cancer.

Brenda Diergaarde, J. Grandis, B. Diergaarde, 2010, Oncology.

Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 1–3, 2010

P. Glazer, J. Grandis, Q. Le, 2011, Radiation research.

Radiation Resistance in Cancer Therapy: Meeting

P. Glazer, J. Grandis, Q. Le, 2011 .

EGFR-mediated cell cycle regulation.

Vivian Wai Yan Lui, J. Grandis, Jennifer Rubin Grandis, 2002, Anticancer research.

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4

J. Grandis, Daniel E. Johnson, S. Thomas, 2012, Autophagy.

NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma.

J. Grandis, R. Ferris, 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gender Equity in Science and Medicine: Breaking the Impasse.

J. Grandis, 2022, Cancer discovery.

A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN).

D. Heron, J. Grandis, R. Ferris, 2010 .

33 – The Molecular Pathogenesis of Head and Neck Cancer

J. Grandis, M. Hedberg, 2015 .

Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

J. Grandis, D. Tweardy, E. Barnes, 1996, Cancer.

Critical analysis of the potential for targeting STAT3 in human malignancy

J. Grandis, N. Peyser, 2013 .

Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit.

J. Grandis, U. Duvvuri, J. Ohr, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

J. Grandis, D. Tweardy, D J Tweardy, 1993, Cancer research.

New insights into RAS in head and neck cancer.

J. Grandis, J. Hess, M. Elkabets, 2023, Biochimica et biophysica acta. Reviews on cancer.

The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck.

D. Hayes, J. Grandis, A. El-Naggar, 2013 .

Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.

J. Grandis, D. Tweardy, Q. Zeng, 1998, International journal of oncology.

Epidermal Growth Factor Receptor–Mediated Stat3 Signaling Blocks Apoptosis in Head and Neck Cancer

J. Grandis, Q. Zeng, S. Drenning, 2000, The Laryngoscope.

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

J. Grandis, D. Tweardy, A. Chakraborty, 1998, The Journal of clinical investigation.

BASIC SCIENCE REVIEW

J. Grandis, R. Ferris, J. Myers, 2005 .

Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.

J. Grandis, A. Wells, J. Kassis, 2003, Cancer research.

Abstract 3821: A prognostic model of head and neck cancer ties TP53 mutation to 3p loss

Andrew M. Gross, Charles S. Coffey, T. Ideker, 2014 .

An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies

Waqas Amin, Anil V Parwani, Hyunseok P Kang, 2009, BMC Cancer.

MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer

J. Grandis, R. Ferris, Jingjing Xu, 2015, BMC Cancer.

Correction: HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

J. Siegfried, A. Egloff, R. Seethala, 2010, Clinical Cancer Research.

Jak/STAT Signaling in HNC

J. Grandis, Bhavana S. Vangara, 2014 .

BASIC SCIENCE REVIEW

J. Grandis, A. Shaha, K. Devaney, 2005 .

Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond.

J. Grandis, Francesca M. Coppelli, 2005, Current pharmaceutical design.

MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin

Kelsey P. Pendleton, A. Egloff, J. Grandis, 2016, Oncotarget.

through enhanced

Kelsey P. Pendleton, J. Grandis, Y. Wen, 2016 .

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

J. Grandis, Hua Li, C. Arteaga, 2016, Cancer research.

MicroRNA‐137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck

R. Stone, R. Seethala, J. Grandis, 2011, Cancer.

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies

Lin Wang, J. Grandis, Hua Li, 2015, Clinical Cancer Research.

2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway.

P. Wipf, J. Grandis, D. Huryn, 2014, Bioorganic & medicinal chemistry letters.

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

A. McKenna, A. Sivachenko, K. Cibulskis, 2011, Science.

High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.

J. Grandis, J. Lazo, P. Johnston, 2018, Methods in molecular biology.

HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

J. Grandis, Netanya I Pollock, 2014, Clinical Cancer Research.

Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit.

J. Grandis, U. Duvvuri, J. Ohr, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Emerging drugs to treat squamous cell carcinomas of the head and neck

J. Grandis, C. Fung, 2010, Expert opinion on emerging drugs.

Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

R. Seethala, Lin Wang, J. Grandis, 2011, Oral oncology.

Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN).

D. Heron, J. Grandis, R. Ferris, 2010 .

Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis

Helen X. Chen, J. Grandis, Seungwon Kim, 2008 .

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

J. Grandis, Hua Li, C. Arteaga, 2016, Cancer research.

Networking practices and gender inequities in academic medicine: Women's and men's perspectives

J. Grandis, Marie Murphy, D. Dohan, 2022, EClinicalMedicine.

Cancer genomics: Spot the difference

Jennifer R. Grandis, J. Grandis, Noah D. Peyser, 2017, Nature.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

J. Grandis, A. Argiris, J. Bauman, 2016, Head & neck.

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Simion I. Chiosea, R. Herbst, Lin Wang, 2016, The Journal of clinical investigation.

Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer

J. Grandis, Anirban Sahu, N. Bhola, 2012, Molecular Cancer Therapeutics.

Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab

R. Seethala, J. Grandis, A. Argiris, 2011, Clinical Cancer Research.

Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC)

D. Heron, M. Karamouzis, J. Grandis, 2007 .

Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome

R. Dhir, J. Siegfried, J. Grandis, 2010, Clinical Cancer Research.

STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer.

J. Grandis, Hua Li, J. Bauman, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.